Individualised medicine: why we need Bayesian dosing

Intern Med J. 2017 May;47(5):593-600. doi: 10.1111/imj.13412.

Abstract

Individualised drug dosing has been shown to improve patient outcomes and reduce adverse drug events. One method of individualised medicine is the Bayesian approach, which uses prior information about how the population responds to therapy, to inform clinicians about how a specific individual is responding to their current therapy. This information is then used to make changes to the dose. Studies using a Bayesian approach to adjust drug dosing have shown that clinicians are able to achieve a therapeutic range quicker than standard practice. If concentration is related to a pharmacodynamic end-point, this means that the drug will be more effective, and the side-effects will be minimised. Unfortunately, the software options to assist with Bayesian dosing in Australia are limited. The aims of this article are to demystify the concepts of Bayesian dosing, set the context of the Bayesian approach using reference to other dosing strategies and discuss its benefits over current dosing methods for a number of drugs. The article is targeted to medical and pharmacy clinicians, and there is a practical clinical case to demonstrate how this method could be used in everyday clinical practice.

Keywords: Bayesian; individualised drug dosing.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Aged
  • Bayes Theorem*
  • Dose-Response Relationship, Drug
  • Enoxaparin / administration & dosage*
  • Enoxaparin / blood*
  • Humans
  • Male
  • Precision Medicine / methods*
  • Pulmonary Embolism / diagnosis
  • Pulmonary Embolism / drug therapy
  • Vancomycin / administration & dosage
  • Vancomycin / blood
  • Warfarin / administration & dosage*
  • Warfarin / blood*

Substances

  • Enoxaparin
  • Warfarin
  • Vancomycin